MorphoSys has enrolled the first patient in its Phase Ib/IIa clinical trial of its lead drug targeting rheumatoid arthritis (RA).
Its MOR103 antibody is being developed in the area of inflammatory diseases such as RA, where existing treatment options are inadequate.
MorphoSys chief development officer Dr Arndt Schottelius said that the company is pleased the trial is beginning according to plan.
“This is an important step for MorphoSys, since we will test an antibody from our growing proprietary pipeline for the first time in patients. We have made significant progress in bringing a potential future drug with a promising new mechanism of action closer to patients,” Schottelius said.